v3.26.1
Business Segments
 12 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Business Segments Business Segments
Segment information has been prepared in accordance with the Segment Reporting topic of FASB ASC 280. Our reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. The primary measure used by our chief operating decision maker ("CODM") to evaluate the performance of our operating segments and allocate resources to these segments is contribution margin, which we define as gross profit less advertising and marketing expenses. Information regarding total assets by operating segment is not provided to our CODM. Our CODM is our President and Chief Executive Officer.
  
The tables below summarize information about our operating and reportable segments.

 Year Ended March 31, 2026
(In thousands)North American OTC
Healthcare		International OTC
Healthcare		Consolidated
Total segment revenues*$913,576 $175,129 $1,088,705 
Cost of sales412,699 80,428 493,127 
Gross profit500,877 94,701 595,578 
Advertising and marketing120,847 27,935 148,782 
Contribution margin$380,030 $66,766 446,796 
Other operating expenses 137,387 
Operating income $309,409 
*Intersegment revenues of $3.8 million were eliminated from the North American OTC Healthcare segment.

 Year Ended March 31, 2025
(In thousands)North American OTC
Healthcare		International OTC
Healthcare		Consolidated
Total segment revenues*$960,010 $177,752 $1,137,762 
Cost of sales428,871 74,428 503,299 
Gross profit531,139 103,324 634,463 
Advertising and marketing129,431 26,292 155,723 
Contribution margin$401,708 $77,032 478,740 
Other operating expenses**141,965 
Operating income$336,775 
* Intersegment revenues of $3.9 million were eliminated from the North American OTC Healthcare segment.
**Other operating expenses for the year ended March 31, 2025 includes a tradename impairment charge of $12.5 million

 Year Ended March 31, 2024
(In thousands)North American OTC
Healthcare		International OTC
Healthcare		Consolidated
Total segment revenues* $958,260 $167,097 $1,125,357 
Cost of sales429,361 71,548 500,909 
Gross profit528,899 95,549 624,448 
Advertising and marketing131,494 21,821 153,315 
Contribution margin$397,405 $73,728 471,133 
Other operating expenses128,704 
Operating loss$342,429 
*Intersegment revenues of $3.7 million were eliminated from the North American OTC Healthcare segment.
The tables below summarize information about our segment revenues from similar product groups.

Year Ended March 31, 2026
(In thousands)North American OTC
Healthcare		International OTC
Healthcare		Consolidated
Analgesics$108,300 $5,636 $113,936 
Cough & Cold76,878 25,031 101,909 
Women's Health205,053 22,712 227,765 
Gastrointestinal179,300 80,488 259,788 
Eye & Ear Care126,132 16,807 142,939 
Dermatologicals116,618 9,313 125,931 
Oral Care86,958 14,093 101,051 
Other OTC14,337 1,049 15,386 
Total segment revenues$913,576 $175,129 $1,088,705 

Year Ended March 31, 2025
(In thousands)North American OTC
Healthcare		International OTC
Healthcare		Consolidated
Analgesics$112,173 $5,524 $117,697 
Cough & Cold82,533 23,681 106,214 
Women's Health216,335 20,496 236,831 
Gastrointestinal174,891 81,052 255,943 
Eye & Ear Care158,858 24,464 183,322 
Dermatologicals120,770 8,177 128,947 
Oral Care81,868 13,162 95,030 
Other OTC12,582 1,196 13,778 
Total segment revenues$960,010 $177,752 $1,137,762 

Year Ended March 31, 2024
(In thousands)North American OTC
Healthcare		International OTC
Healthcare		Consolidated
Analgesics$111,996 $5,455 $117,451 
Cough & Cold93,575 25,445 119,020 
Women's Health217,103 23,318 240,421 
Gastrointestinal160,889 70,721 231,610 
Eye & Ear Care156,553 22,870 179,423 
Dermatologicals123,288 5,814 129,102 
Oral Care83,212 13,093 96,305 
Other OTC11,644 381 12,025 
Total segment revenues$958,260 $167,097 $1,125,357 

Our total segment revenues by geographic area are as follows:
Year Ended March 31,
202620252024
United States$850,414 $897,540 $886,470 
Rest of world238,291 240,222 238,887 
Total$1,088,705 $1,137,762 $1,125,357 
Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:

March 31, 2026
(In thousands)
North American OTC
Healthcare		International OTC
Healthcare		Consolidated
Goodwill$550,987 $30,122 $581,109 
Intangible assets 
Indefinite-lived2,068,752 74,923 2,143,675 
Finite-lived138,903 17,027 155,930 
Intangible assets, net2,207,655 91,950 2,299,605 
Total$2,758,642 $122,072 $2,880,714 

March 31, 2025
(In thousands)
North American OTC
Healthcare		International OTC
Healthcare		Consolidated
Goodwill$498,936 $28,489 $527,425 
Intangible assets 
Indefinite-lived2,068,752 68,234 2,136,986 
Finite-lived141,234 17,130 158,364 
Intangible assets, net2,209,986 85,364 2,295,350 
Total$2,708,922 $113,853 $2,822,775 

Our goodwill and intangible assets by geographic area are as follows:
Year Ended March 31,
20262025
United States$2,706,591 $2,708,922 
Rest of world174,123 113,853 
Total$2,880,714 $2,822,775